Role of heterotrimer G protein in podocyte injury
10.12092/j.issn.1009-2501.2024.02.008
- Author:
Can LIU
1
;
Enlai DAI
1
;
Zhaoran DING
1
;
Shuwen DUAN
1
;
Xiaohui WANG
1
;
Enlai DAI
2
Author Information
1. School of Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine
2. Department of Nephrology, Affiliated Hospital of Gansu University of Chinese Medicine
- Publication Type:Journal Article
- Keywords:
G protein-coupled receptor;
heterotrimeric G protein;
podocyte injury
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(2):177-187
- CountryChina
- Language:Chinese
-
Abstract:
GPCRs are the largest membrane protein receptor superfamily in the human body, with more than 800 isoforms, and approximately 35% of Food and Drug Administration-approved and marketed drugs currently target GPCRs for the treatment of a wide range of diseases, for heart failure (beta-adrenergic receptors), peptic ulcer (histamine receptors), prostate cancer (gonadotropin receptors), hypertension (adrenergic and angiotensin receptors), pain (opioid receptors), and bronchial asthma (beta2-adrenergic receptors) examples. Although the number of GPCRs is enormous, the signaling proteins downstream of them are limited, heterotrimeric G proteins (GPs) are key proteins that signal GPCRs, translate extracellular stimuli into intracellular responses by coupling to GPCRs and initiate multiple signaling events via downstream cascades. Podocytes are an important component of the glomerular filtration barrier, and their damage is a central event in proteinuria formation and progressive glomerulosclerosis. This article reviews the regulation of GPs, their signaling and their role in podocyte injury to provide a theoretical basis for scientific research and clinical treatment of this disease.
